CBM BIOPHARMA

The CBM drug portfolio focuses on the treatment of three cancers, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and pancreatic cancer. Our AML drug is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care. Our pancreatic treatment has shown positive preclinical results for inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models. The drug has also demonstrated the potential to overcome tumor cell resistance to current chemotherapeutic drugs.